AerCap Holdings reported Q2 earnings on July 29, and the stock's reaction tells the story: up 1.8% on the day to $154.09, extending a week that added another 1.5% and a month that has produced a 3.5% gain.
The pre-earnings note from July 26 flagged an unusually bullish analyst setup and call-heavy options positioning. Both proved well-placed. The print landed in line with the constructive setup, and short sellers continued their retreat — short interest has now fallen 29% over the past month to just 0.67% of the free float, the lowest level in the 30-day window. Bears have been quietly covering, not building. Borrowing costs have halved over the past week to a negligible 0.20%, and availability has exploded to over 8,000% — meaning for every share currently borrowed, there are more than 80 available to borrow. The lending market has never been looser for this stock, at least by the standards of the past year.
Options positioning remains firmly call-tilted. The put/call ratio came in at 0.33 on the close, still well below its 20-day average of 0.46 and roughly 1.3 standard deviations beneath it. That's a slight uptick from the 0.32 and 0.32 readings on Monday and Tuesday — the PCR collapsed sharply when AER entered its final pre-earnings stretch around July 17, falling from the mid-0.50s where it had traded for most of July. The shift was abrupt and sustained. Call demand has not unwound post-print, which suggests the market is not treating this as a "sell the news" setup.
The Street angle now deserves a closer read, because the earnings move has created a mild but notable gap. The mean analyst price target is $168.80, implying roughly 10% upside from $154.09. But several recently raised targets — Barclays at $179, TD Cowen at $180, Truist at $175 — were set before the Q2 print with the stock trading closer to $151. With the stock now $3 higher and earnings behind it, some of those targets look more like post-results confirmations than forward-looking upside calls. Citigroup's July 20 initiation at Buy with a $173 target is the freshest, and it still offers roughly 12% upside. Morgan Stanley holds its Equal-Weight at $155 — now barely above the current price — and remains the lone dissenter. Factor scores broadly support the bull case: EPS surprise ranks in the 82nd percentile, analyst recommendation divergence hits the 93rd percentile, and the dividend score sits at 92. The PE has crept up to 8.9x on the price move, and EV/EBITDA has ticked higher over the past month, but valuation remains undemanding for a lessor of this scale.
CEO Aengus Kelly sold just over $3.7 million in shares in early May. The CFO sold approximately $11 million across several tranches on May 12. Neither sale looks exceptional given the scale of their holdings — Kelly retains 4.2% of the company, a position worth north of $1 billion at current prices. The net insider position over 90 days is technically positive at roughly $48 million, reflecting earlier vesting activity that outweighs the open-market sales. The more notable ownership signal is that BlackRock added 281,000 shares through June 30, Franklin Resources added 383,000, and JP Morgan Asset Management added 375,000 — all three moving in the same direction in the most recent reporting period.
The question now is whether targets get revised upward in the next 48-72 hours as analysts digest the Q2 print, and whether Morgan Stanley's Equal-Weight — sitting just $1 above the current price — becomes harder to hold.
See the live data behind this article on ORTEX.
Open AER on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
